Pennsylvanians who purchased certain generic prescription drugs between May 2009 and December 2019 may be eligible for compensation from roughly $25 million to $30 million in recovered consumer restitution funds, according to the Pennsylvania Attorney General’s Office. The payouts stem from ongoing antitrust lawsuits and settlements involving generic drug manufacturers accused of conspiring to inflate prices.
Court Approval and Distribution Plans
The U.S. District Court for the District of Connecticut granted preliminary approval to a distribution plan filed by Pennsylvania and a coalition of 47 other states and territories, according to the article. Pennsylvania Attorney General Dave Sunday encouraged qualifying residents to check their eligibility promptly, noting that the window to act is short.
“Pennsylvanians who purchased certain generic prescription drugs during a 10-year-period beginning in 2009 may be entitled to compensation, so I encourage them to act fast,” Sunday said. Consumers can review covered medications, check eligibility, and file claims at the official website, AGGenericDrugs.com, or contact administrators by calling 1-866-290-0182.
Qualifying Medications and Claim Options
The settlement list includes many commonly prescribed medications, such as generic versions of albuterol, cipro, prednisone, and levothyroxine.
- Receiving an equal share of the available settlement funds among eligible claimants.
- Reporting an estimated out-of-pocket payment amount for eligible medications, which could result in a larger payment but requires supporting documentation such as insurance records.
Consumers do not necessarily need old receipts if they choose the equal-share distribution option.
Pro Tip: Watch out for lookalike URLs in search engines.
Origins of the Multi-State Antitrust Litigation
The payouts follow a series of antitrust actions launched in 2016 by state attorneys general against generic pharmaceutical companies. The initial complaint named Heritage Pharmaceuticals, 17 other corporate defendants, two individual defendants, and 15 generic drugs. Subsequent complaints expanded the litigation significantly:
- Second Complaint (2019): Named Teva Pharmaceuticals, 21 other generic manufacturers, and 16 individual executives.
- Third Case: Focuses on 80 topical generic drugs, naming 26 corporate defendants and 10 individual defendants.
- Fourth Complaint: Filed earlier this year, alleging that Novartis AG, Sandoz Group AG, and Sandoz AG are liable for conduct involving Sandoz and the fraudulent transfer of assets.
The multi-state coalition previously announced settlements totaling approximately $96.5 million with companies including Glenmark, Lannett, Bausch, Apotex, Heritage, and Emcure, according to the article. State investigations utilized millions of documents, phone records, and cooperating witnesses—including seven pharmaceutical executives—to uncover alleged agreements among competing companies to limit competition and raise prices.
Frequently Asked Questions
Who qualifies for the generic drug settlement?
Consumers who purchased certain generic prescription drugs between May 2009 and December 2019 may be eligible to file a claim, according to the Pennsylvania Attorney General’s Office.
What is the deadline to file a claim?
Eligible consumers must submit their claims before the March 8 deadline.
Do I need receipts to get money?
No. Claimants can choose to receive an equal share of the settlement funds without submitting receipts, or they can provide out-of-pocket estimates supported by documentation like insurance records for a potentially larger payout.
Where can I check if my medication is on the list?
You can search for specific prescription names and check eligibility directly at the official portal, AGGenericDrugs.com.
Have you checked your eligibility for the generic drug settlements yet? Share your thoughts or questions in the comments below, and subscribe to our newsletter for ongoing consumer updates.
Related reading